No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 14 of the 40 quarters in the window, leaving 26 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 37
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T22:04:17.024Z. Latest historical point 2023-11-07. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Summit Therapeutics Inc. (SMMT) stock was $17.31 as of Oct 6, 2026, 4:00 PM EDT, up 0.23% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -19.3% · 3-year avg +112.1%/yr · 5-year avg +28.1%/yr
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America.
Biotechnology · Miami, FL
LATEST PRICE
$17.31
52-WEEK RANGE
$12.07 - $29.23
BETA
-1.24
% FROM 52W HIGH
-40.78%
MARKET CAP
$13.81B
DIVIDEND YIELD
Never paid
N/A
PE RATIO
trailing TTM
N/A
PE RATIO (FWD)
forward FY estimate
N/A
P/B RATIO
21.92
P/S RATIO
TTM
N/A
P/OCF RATIO
TTM
N/A
EV/EBITDA
TTM
N/A
DEBT / EQUITY
0.03
REVENUE TTM
$0
GROSS MARGIN TTM
0.00%
NET PROFIT MARGIN TTM
0.00%
REVENUE GROWTH TTM
TTM vs prior TTM
N/A
REVENUE CAGR 3Y
N/A
REVENUE CAGR 5Y
N/A
TTM TOTAL RETURN
-19.33%
3Y TOTAL RETURN
annualized (CAGR)
+112.06%
5Y TOTAL RETURN
annualized (CAGR)
+28.09%
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2022-12-31 · GBP
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2022-12-31 · GBP
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Oct 19, 2026
13 days away
EPS Estimate
-0.28
Revenue Est.
$71429.00
Last Quarter Results
EPS
$-0.21
vs Estimate
$-0.21
Revenue
$0.00
vs Estimate
$113889.00
Consensus Rating
Based on 13 analysts
Average Price Target
$29.87
+72.6% upside
Low
$11.94
Current
$17.31
High
$43.22
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.30 | $-0.29 | $-0.28 | 7 |
| Quarter ending Dec 2026 | $-0.57 | $-0.35 | $-0.24 | 7 |
| Quarter ending Mar 2027 | $-0.47 | $-0.29 | $-0.12 | 2 |
| Quarter ending Jun 2027 | $-0.47 | $-0.29 | $-0.12 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.43 | $-1.17 | $-1.03 | 9 |
| FY 2027 | $-1.35 | $-1.13 | $-0.95 | 8 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $38469.00 | $71429.00 | $104388.00 | 14 |
| Quarter ending Dec 2026 | $2.14M | $3.97M | $5.80M | 8 |
| Quarter ending Mar 2027 | $5.95M | $11.05M | $16.14M | 4 |
| Quarter ending Jun 2027 | $9.35M | $17.36M | $25.37M | 5 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $1.97M | $3.66M | $5.34M | 10 |
| FY 2027 | $59.40M | $59.53M | $59.66M | 10 |
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1SMMT | $13.81B | $17.31 | +0.23% | -19.33% | +28.09% | +1.87% | N/A |
| 2ASND | $14.04B | $226.05 | -0.87% | +11.69% | +7.40% | +27.41% | vs SMMT |
| 3BBIO | $13.11B | $66.96 | +1.24% | +24.99% | +7.38% | N/A | vs SMMT |
| 4JAZZ | $14.54B | $231.39 | -1.97% | +68.80% | +13.01% | +6.58% | vs SMMT |
| 5HALO | $13.01B | $109.72 | +1.30% | +56.68% | +22.18% | +24.30% | vs SMMT |
| 6NBIX | $14.63B | $145.51 | +0.90% | +5.21% | +7.56% | +10.90% | vs SMMT |
